Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: Dose schedules and results

YF Liaw; IS Sheen

doi:10.1016/0168-8278(90)90190-3

Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: Dose schedules and results

YF Liaw^*, IS Sheen

^*Corresponding author for this work

Chang Gung Memorial Hospital

Research output: Contribution to journal › Journal Article › peer-review

2 Scopus citations

Abstract

• ■ Response rate: 50-65% (87.5% within 2 months). • ■ Relapse in 80% after down titration, 80% response again on up titration. • ■ Relapse after end of treatment: 55%, usually transient.

Original language	English
Pages (from-to)	S160
Journal	Journal of Hepatology
Volume	11
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/0168-8278(90)90190-3
State	Published - 1990
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0168-8278(90)90190-3

Cite this

@article{d1697ce0ebea4084802485d13f12c979,

title = "Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: Dose schedules and results",

abstract = "• ■ Response rate: 50-65% (87.5% within 2 months). • ■ Relapse in 80% after down titration, 80% response again on up titration. • ■ Relapse after end of treatment: 55%, usually transient.",

author = "YF Liaw and IS Sheen",

year = "1990",

doi = "10.1016/0168-8278(90)90190-3",

language = "英语",

volume = "11",

pages = "S160",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis

T2 - Dose schedules and results

AU - Liaw, YF

AU - Sheen, IS

PY - 1990

Y1 - 1990

N2 - • ■ Response rate: 50-65% (87.5% within 2 months). • ■ Relapse in 80% after down titration, 80% response again on up titration. • ■ Relapse after end of treatment: 55%, usually transient.

AB - • ■ Response rate: 50-65% (87.5% within 2 months). • ■ Relapse in 80% after down titration, 80% response again on up titration. • ■ Relapse after end of treatment: 55%, usually transient.

UR - http://www.scopus.com/inward/record.url?scp=0025688635&partnerID=8YFLogxK

U2 - 10.1016/0168-8278(90)90190-3

DO - 10.1016/0168-8278(90)90190-3

M3 - 文章

AN - SCOPUS:0025688635

SN - 0168-8278

VL - 11

SP - S160

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - SUPPL. 1

ER -

Randomized controlled trial of recombinant interferon alfa-2b in chronic NANB hepatitis: Dose schedules and results

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this